Source: Eur Respir J, 53 (4) 1802066; 10.1183/13993003.02066-2018



Rating:

Share or cite this content

Citations should be made in the following way:
Nishant Gupta, Hye-Seung Lee, Lisa R. Young, Charlie Strange, Joel Moss, Lianne G. Singer, Koh Nakata, Alan F. Barker, Jeffrey T. Chapman, Mark L. Brantly, James M. Stocks, Kevin K. Brown, Joseph P. Lynch, Hilary J. Goldberg, Gregory P. Downey, Angelo M. Taveira-DaSilva, Jeffrey P. Krischer, Kenneth Setchell, Bruce C. Trapnell, Yoshikazu Inoue, Francis X. McCormack. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J, 53 (4) 1802066; 10.1183/13993003.02066-2018

Member's Comments

No comment yet.

Related content which might interest you: Risk factors for lung disease progression in children with cystic fibrosis; a longitudinal cohort study Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 Identification and analysis of clinical phenotypes in COPD patients: PALOMB Cohort Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Disease progression at 12 months does not predict future outcomes in IPF patients: Analysis from the Australian IPF Registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Blood biomarkers predicting disease progression in patients with IPF: data from the INMARK trial Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 CF-ABLE-UK score: Modification and validation of a clinical prediction rule for prognosis in cystic fibrosis on data from UK CF registry Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 Risk factors for active tuberculosis in patients with inflammatory bowel disease: A case-control study Source: International Congress 2015 – Latent TB infection and screening Year: 2015 Identification of clinical phenotypes in patients with and without COPD using cluster analysis Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort Source: International Congress 2016 – The best is yet to come in terms of lung function Year: 2016 Presence of concurrent sarcoid-like granulomas indicates better survival in cancer patients: a retrospective cohort study Source: ERJ Open Res, 6 (4) 00061-2020; 10.1183/23120541.00061-2020 Year: 2020 Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis?  Real- world results from the EMPIRE registry. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study Source: Eur Respir J, 58 (3) 2002288; 10.1183/13993003.02288-2020 Year: 2021 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 Rheumatoid arthritis-related interstitial lung disease (RA-ILD): Clinical, functional features, and variables associated poor initial prognosis in a chilean cohort Source: Virtual Congress 2020 – Clinical aspects and new treatment strategies for rare interstitial lung diseases in adults and children Year: 2020 Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Monitoring disease progression in patients with biopsy proven cases of sarcoidosis: A survey Source: Annual Congress 2010 - Sarcoidosis: from the bench to the bedside Year: 2010 MUC2MUC5B and TOLLIP variants: no association with disease progression and survival in an IPF cohort Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis Year: 2020 Late Breaking Abstract - A composite serum biomarker index for the diagnosis of systemic sclerosis associated interstitial lung disease: a multicentre, observational, cohort study Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Prognostic factors affecting survival of idiopathic pulmonary fibrosis in Korean population Source: Eur Respir J 2007; 30: Suppl. 51, 578s Year: 2007